To study whether treatment with PARPi affects inflammatory responses, Alvarado-Cruz et al. (2021) interrogated BRCA1-mutant triple negative breast cancer (TNBC) cell lines and tumours samples after treatment with veliparib for three weeks. The gene discussed is BRCA1; the disease is neoplasm.